CN119317624A - 用于生产奥希替尼的改进方法 - Google Patents

用于生产奥希替尼的改进方法 Download PDF

Info

Publication number
CN119317624A
CN119317624A CN202380044986.XA CN202380044986A CN119317624A CN 119317624 A CN119317624 A CN 119317624A CN 202380044986 A CN202380044986 A CN 202380044986A CN 119317624 A CN119317624 A CN 119317624A
Authority
CN
China
Prior art keywords
formula
compound
salt
reaction
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380044986.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·K·穆伦
A·波佐利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN119317624A publication Critical patent/CN119317624A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN202380044986.XA 2022-04-07 2023-04-06 用于生产奥希替尼的改进方法 Pending CN119317624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362622P 2022-04-07 2022-04-07
US63/362622 2022-04-07
PCT/EP2023/059132 WO2023194531A1 (en) 2022-04-07 2023-04-06 Improved process for the manufacture of osimertinib

Publications (1)

Publication Number Publication Date
CN119317624A true CN119317624A (zh) 2025-01-14

Family

ID=86142780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380044986.XA Pending CN119317624A (zh) 2022-04-07 2023-04-06 用于生产奥希替尼的改进方法

Country Status (14)

Country Link
US (1) US20250250255A1 (https=)
EP (1) EP4504718A1 (https=)
JP (1) JP2025511404A (https=)
KR (1) KR20250002363A (https=)
CN (1) CN119317624A (https=)
AR (1) AR128999A1 (https=)
AU (1) AU2023250220A1 (https=)
CA (1) CA3255378A1 (https=)
CO (1) CO2024015096A2 (https=)
IL (1) IL316018A (https=)
MX (1) MX2024012370A (https=)
TW (1) TW202404955A (https=)
WO (1) WO2023194531A1 (https=)
ZA (1) ZA202408113B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120717920A (zh) * 2025-08-18 2025-09-30 爱斯特（成都）生物制药股份有限公司 一种微通道连续合成3-硝基-4-氟苯腈的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN106883216B (zh) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法
IN201741031902A (https=) * 2017-09-08 2019-03-15 Msn Laboratories Private Ltd
CN109134435B (zh) 2018-10-29 2023-01-03 湖南大学 一种奥希替尼azd9291的合成方法

Also Published As

Publication number Publication date
JP2025511404A (ja) 2025-04-15
AR128999A1 (es) 2024-07-03
ZA202408113B (en) 2025-07-30
KR20250002363A (ko) 2025-01-07
TW202404955A (zh) 2024-02-01
WO2023194531A1 (en) 2023-10-12
MX2024012370A (es) 2024-11-08
AU2023250220A1 (en) 2024-11-07
IL316018A (en) 2024-11-01
CO2024015096A2 (es) 2024-11-28
EP4504718A1 (en) 2025-02-12
CA3255378A1 (en) 2023-10-12
US20250250255A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
US8076476B2 (en) Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
CN111333633A (zh) 一种瑞卢戈利的中间体化合物及其制备方法和用途
JP6175122B2 (ja) ２−アミノ−ｎ−（２，２，２−トリフルオロエチル）アセトアミドの調製方法
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
EA019058B1 (ru) Способ получения кристаллических форм а и в илапразола и способ превращения указанных кристаллических форм
KR20150041650A (ko) (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 및 이의 약학적으로 허용가능한 형태의 제조를 위한 공정
CN105906628B (zh) 一种利格列汀的制备方法
CN119317624A (zh) 用于生产奥希替尼的改进方法
CN112661757B (zh) 一种盐酸缬更昔洛韦的合成方法
ES2748324T3 (es) Método para producir un compuesto de indol
CN115073490A (zh) 一种瑞卢戈利及其中间体的制备方法
CN116535384A (zh) 替卡格雷中间体的制备方法
CN115073491A (zh) 一种瑞卢戈利中间体、其制备方法及其应用
CN115477653B (zh) 一种曲拉西利关键中间体及曲拉西利的制备方法
JPWO2002018403A1 (ja) エリスロマイシン誘導体の製造方法
CN111574463A (zh) 一种利格列汀中间体化合物ⅳ
CN104672239A (zh) 一种采用一锅法制备阿巴卡韦式v中间体的工艺
US8124776B2 (en) Process and intermediates for preparing arzoxifene
CN113024521B (zh) 一种制备恩曲替尼的方法
RU2450009C2 (ru) Способ синтеза противораковых производных (поли)аминоалкиламиноацетамида эпиподофиллотоксина
US9040697B2 (en) Process for the production of moxonidine
US20050070586A1 (en) Process for the synthesis of losartan potassium
JP2001526253A (ja) イソプロピル−メチル−［２−（３−ｎ−プロポキシフェノキシ）エチル］アミンの製造方法
CN107056767A (zh) 用于制备水溶性紫杉烷类衍生物的方法及中间体
CN117603201A (zh) 一种适合产业化制备阿齐沙坦酯的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination